"It is very likely that Ozempic will be part of negotiations in the coming round, and we're ready for that," said Ulrich Otte of Novo Nordisk. The executive confirmed the company's preparedness to engage in negotiations regarding the drug's pricing as part of the upcoming policy changes dictated by the Biden administration's Inflation Reduction Act.
The law allows the US government to haggle over drug prices, a practice already common in many other nations. This shift marks a significant change in the pharmaceutical landscape within the United States.
Ozempic, which is primarily used to manage type 2 diabetes, has a list price of $968.52 monthly. Its inclusion in bargaining is expected by health-care analysts, reflecting growing scrutiny on drug pricing.
The US Centers for Medicare and Medicaid Services will announce new drugs for negotiation by February 1, 2025, and will set maximum fair prices by November 30, 2025.
Collection
[
|
...
]